Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.300 GeneticVariation disease UNIPROT
CUI: C1862939
Disease: AMYOTROPHIC LATERAL SCLEROSIS 1
AMYOTROPHIC LATERAL SCLEROSIS 1 		0.300 Biomarker disease CTD_human Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. 11796754 2002
CUI: C1862941
Disease: Amyotrophic Lateral Sclerosis, Sporadic
Amyotrophic Lateral Sclerosis, Sporadic 		0.300 Biomarker disease CTD_human Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. 11796754 2002
CUI: C4551993
Disease: Amyotrophic Lateral Sclerosis, Familial
Amyotrophic Lateral Sclerosis, Familial 		0.300 Biomarker disease CTD_human Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. 11796754 2002
CUI: C0003467
Disease: Anxiety
Anxiety 		0.100 GeneticVariation disease GWASCAT Meta-analysis of genome-wide association studies for neuroticism in 449,484 individuals identifies novel genetic loci and pathways. 29942085 2018
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.060 Biomarker disease BEFREE In INA-6 cells and primary myeloma cells, janus kinase 2 (JAK-2) and extracellular signal regulated kinase 1 and 2 (ERK-1/2) were phosphorylated by rhEPO treatment. 27581518 2016
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.060 Biomarker disease BEFREE Using the INA-6 cell line as the MM model and the strictly HSF1-dependent HSP72 induction as a HSR model, we identified potential HSF1 inhibitors. 28453931 2017
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.060 GeneticVariation disease BEFREE To identify antibodies suitable for multiple myeloma (MM) immunotherapy, a cellular screening approach was developed using plasma cell lines JK-6L and INA-6 and human synthetic single-chain fragment variable (scFv) phage libraries. 29100408 2017
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.060 Biomarker disease BEFREE Eight further known naphthylisoquinolines were isolated from A. ileboensis, among them dioncophylline A (P-10), its 4'-O-demethyl analogue P-11, and 5'-O-methyldioncophylline D (7), which were found to display strong cytotoxic activities against multiple myeloma INA-6 cells (P-10 even stronger than the standard drug melphalan) and against drug-sensitive acute lymphoblastic CCRF-CEM leukemia cells and their multidrug-resistant subline, CEM/ADR5000. 28121440 2017
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.060 Biomarker disease BEFREE The myeloma cell lines ANBL-6 and INA-6 adhered to OPN. 15003892 2004
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.060 Biomarker disease BEFREE Similarly, p110delta specific small molecule inhibitor CAL-101 triggered cytotoxicity against LB and INA-6 MM cell lines and patient MM cells, associated with inhibition of Akt phosphorylation. 20505158 2010
CUI: C0028945
Disease: oligodendroglioma
oligodendroglioma 		0.040 AlteredExpression disease BEFREE Remarkably, most of the genes showing distinctive expression in oligodendroglioma with 1p loss were also highly expressed in normal brain tissues and had neuron-related function, which included MYT1L, INA, RIMS2, SNAP97 and SNCB. 14997935 2004
CUI: C0028945
Disease: oligodendroglioma
oligodendroglioma 		0.040 Biomarker disease BEFREE alpha-Internexin (INA) is a proneural gene encoding a neurofilament interacting protein that is upregulated in some gliomas, particularly oligodendrogliomas. 19139367 2009
CUI: C0028945
Disease: oligodendroglioma
oligodendroglioma 		0.040 AlteredExpression disease BEFREE Oligodendrogliomas showed strong INA and Olig2 expression, and 1p19q whole loss of heterozygosity (wLOH). 21653654 2011
CUI: C0028945
Disease: oligodendroglioma
oligodendroglioma 		0.040 Biomarker disease BEFREE INA was positive in 80.3% of ODGs and in 34.3% of GBMs. 23579442 2013
CUI: C0751396
Disease: Well Differentiated Oligodendroglioma
Well Differentiated Oligodendroglioma 		0.040 Biomarker disease BEFREE INA was positive in 80.3% of ODGs and in 34.3% of GBMs. 23579442 2013
CUI: C0751396
Disease: Well Differentiated Oligodendroglioma
Well Differentiated Oligodendroglioma 		0.040 AlteredExpression disease BEFREE Oligodendrogliomas showed strong INA and Olig2 expression, and 1p19q whole loss of heterozygosity (wLOH). 21653654 2011
CUI: C0751396
Disease: Well Differentiated Oligodendroglioma
Well Differentiated Oligodendroglioma 		0.040 AlteredExpression disease BEFREE Remarkably, most of the genes showing distinctive expression in oligodendroglioma with 1p loss were also highly expressed in normal brain tissues and had neuron-related function, which included MYT1L, INA, RIMS2, SNAP97 and SNCB. 14997935 2004
CUI: C0751396
Disease: Well Differentiated Oligodendroglioma
Well Differentiated Oligodendroglioma 		0.040 Biomarker disease BEFREE alpha-Internexin (INA) is a proneural gene encoding a neurofilament interacting protein that is upregulated in some gliomas, particularly oligodendrogliomas. 19139367 2009
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.020 AlteredExpression disease BEFREE INA expression was strong (>10% positive cells) in 22 cases (22 oligodendroglial tumors and 0 astrocytic tumors), weak (<10% cells) in 14 cases (12 oligodendroglial tumors, 2 glioblastoma with an oligodendroglial component, and 0 astrocytic tumors), and negative in 86 cases (49 oligodendroglial tumors, 9 glioblastoma with an oligodendroglial component, and 28 astrocytic tumors). 19139367 2009
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.020 Biomarker disease BEFREE INA was positive in 80.3% of ODGs and in 34.3% of GBMs. 23579442 2013
CUI: C0017638
Disease: Glioma
Glioma 		0.020 Biomarker disease BEFREE To assess the relevance of INA immunohistochemistry in glioma typing, this paper studied the relationship between INA expression, histological type, genomic status and patient outcome. 21653654 2011
CUI: C0017638
Disease: Glioma
Glioma 		0.020 AlteredExpression disease BEFREE We analyzed INA expression in 83 glioma and 21 oligodendroglial phenotype-mimicking tumors (OMT) to assess its usefulness in differential diagnosis and its correlation with 1p/19q status; in particular, INA expression in gliomas with isolated/partial 1p or 19q deletions was assessed. 22002423 2011
CUI: C0019243
Disease: Angioedemas, Hereditary
Angioedemas, Hereditary 		0.020 Biomarker disease BEFREE Interaction between C1-INA, coagulation, fibrinolysis and kinin system in hereditary angioneurotic edema (HANE) and urticaria. 6517610 1984
CUI: C0019243
Disease: Angioedemas, Hereditary
Angioedemas, Hereditary 		0.020 AlteredExpression disease BEFREE Incubation of HAE serum resulted in a loss of activity which appears to be dependent upon the concentration of functional C-1-INA. 6733980 1984